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Metastases are responsible for 90% of cancer-related deaths, as they
are resistant to virtually all currently available forms of therapy, surgical
removal being limited to isolated lesions. The complex series of steps,
known as themetastatic cascade, which tumor cells capable of generat-
ing secondary colonies must complete (Chambers et al., 2002; Gupta
and Massagué, 2006; Lambert et al., 2017), led to the notion that meta-
static cells possess unique, genetically determined features distinct from
those of non-metastasizing cells. However, genetic studies, including
large-scale genomic sequencing efforts have failed to uncover
metastasis-speciﬁc mutations (Garraway and Lander, 2013; Vogelstein
et al., 2013). Cancer cells capable of fulﬁlling all of the requirements
for both primary and metastatic growth must therefore reside within
the initial tumormass (Ramaswamy et al., 2003), their metastatic prop-
erties beingmost likely sculpted by epigeneticmechanisms activated by
the initiating oncogenic events themselves or by signals delivered by
the microenvironment (Wan et al., 2013).
The tumormicroenvironment (TME) plays a critical role in metasta-
sis. Tumor growth invariably induces an inﬂammatory and regenerativearticle underresponse, which recapitulates the features of a wound (Chang et al.,
2004), while suppressing the mechanisms that render a wound self-
limiting, leading to the analogy of a “wound that never heals”
(Dvorak, 1986). Elucidation of themechanisms bywhich themicroenvi-
ronment promotes tumor cell dissemination therefore requires thor-
ough understanding of the wound healing process, including the
discrete changes in the stromal cell populations and extracellularmatrix
(ECM) composition that occur as the process evolves (Schäfer and
Werner, 2008).
Host tissue stromal cells provide favorable conditions for tumor cell
dissemination by producing cytokines that promote tumor cell survival
and growth and by secreting proteolytic enzymes that break down
physical barriers to cell migration and release growth factors seques-
tered within the ECM (Quail and Joyce, 2013). Among stromal cells
that promote tumor progression, cancer-associated ﬁbroblasts (CAFs)
are held to play the principal role (Kalluri, 2016). However, CAF is a
loosely used term and in addition to activated ﬁbroblasts, which typi-
cally express α-smooth muscle actin (α-SMA) and are referred to as
myoﬁbroblasts, CAFs include a variety of mesenchymal cells at various
stages of differentiation and with various degrees of plasticity (Kalluri,
2016; Öhlund et al., 2014). The potent regenerative signals of the TME
not only promote cancer cell pluripotency (Taddei et al., 2013) but
also recruit stromal cells associated with tissue regenerationthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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chymal stem cells (MSCs) (Cuiffo and Karnoub, 2012).
Mesenchymal stem cells are heterogeneous stromal cells deﬁned
based on functional and phenotypic criteria, including adherence to
plastic under standard culture conditions, expression of selected cell
surface markers and lack of lineage-speciﬁc markers and the capacity
to differentiate into most mesenchymal lineages (Dominici et al.,
2006; Kobolak et al., 2016). They were initially identiﬁed in the bone
marrow (BM) but subsequently found to be recruited to or to reside in
most tissueswhere they contribute to tissue renovation especially in sit-
uations of acute and chronic injury.Mesenchymal stem cells display tro-
pism for inﬂammatory and tumor sites, where their release of a broad
repertoire of soluble factors canmodulate the immune response and af-
fect tumor cell behavior (Cuiffo and Karnoub, 2012). They can also dif-
ferentiate in situ into a variety of mesenchymal lineages (Bergfeld and
DeClerck, 2010; Cuiffo and Karnoub, 2012) and have been suggested
to promote tumor metastasis (Karnoub et al., 2007; Koh and Kang,
2012) based on models using BM-MSCs and cancer cell lines (Bergfeld
and DeClerck, 2010). Only recently has interest begun to shift toward
the inﬂuence of human tumor associated-MSCs on cancer progression
(Shi et al., 2017; Sun et al., 2014).
We addressed the role of MSCs on the growth and dissemination of
lung cancer, the leading malignancy in terms of lethality worldwide.
More than 85% of lung cancers are non-small cell lung carcinomas
(NSCLC), which are subdivided into adenocarcinoma (AC), squamous
cell carcinoma (SCC) and large cell carcinoma, that comprise about
50%, 40% and b10%of NSCLC, respectively. NSCLC respondpoorly to con-
ventional chemotherapy and although targeted therapy has been suc-
cessful in prolonging survival in a minority of cases (Alamgeer et al.,
2013; Hirsch et al., 2017), the current 5-year survival of NSCLC patients
is lower than 20% (Chen et al., 2014). Small cell lung carcinomas (SCLC),
which comprise the remaining 15% of lung cancers are even more ag-
gressive than NSCLC with extremely high metastatic proclivity and 5-
year patient survival below 7% (Semenova et al., 2015).
Using patient-derived lung cancer samples removed at surgery, we
compared the effect of tumor-associated MSCs (T-MSCs) to that of nor-
mal adjacent lung tissue-derivedMSCs (N-MSCs) on the behavior of au-
tologous primary lung cancer cells. Injection of the tumor cells with
paired T- or N- MSCs into the subcapsular renal compartment of NOD-
SCID- common-γ-KO (NSG) mice revealed that T-MSCs promoted
multi-organ metastasis without augmenting local growth of tumor
cells, which alone displayed low metastatic proclivity. Although T- and
N-MSCs displayed different gene expression proﬁles, in vitro experi-
ments revealed that tumor cells and TME factors participate in promot-
ing N-MSC transition toward a T-MSC phenotype. Conversely, MSCs
caused tumor cells to upregulate genes associated with tumorTable 1
Patient characteristics.
Patient Tumor type




#21 Poorly differentiated SCC
#26 Composite carcinoma (SCLC 60%, NELCd 30%, NSCLC NOSe 10%)
#27 Moderately differentiated SCC
#28 AC
#29 Moderately differentiated SCC
#32 Poorly differentiated SCC
a SCC: Squamous cell carcinoma.
b SCLC: Small cell lung carcinoma.
c AC: Adenocarcinoma.
d NELC: neuroendocrine lung carcinoma.
e NSCLC NOS: non-small cell lung cancer not otherwise speciﬁed.
f TNM classiﬁcation: p: pathological classiﬁcation; T: primary tumor; N: lymph node; M: me
g NA: not available.dissemination. Reconstitution of N-MSCs with four genes, GREM1,
LOXL2, ADAMTS12 and ITGA11 that contributed to the T-MSC phenotype
increased their ability to promote primary tumor cell dissemination.
Our observations provide insight into mechanisms by which MSCs se-
lectively promote cancer metastasis independent of their immunosup-
pressive functions.
2. Experimental Procedures
2.1. Isolation and Characterization of MSCs and Tumor Cells
2.1.1. MSCs
Primary fresh tumor tissues and macroscopically normal adjacent
tissues were obtained from 5 SCC, 3 AC and 2 SCLC patients (Table 1)
by surgical resection at Centre Universitaire Hospitalier Vaudois
(CHUV) with patient signed informed consent according to the guide-
lines of the Ethic committee of Canton de Vaud (project authorization
n° 131/12) and conforming to standards indicated by the Declaration
of Helsinki. MSC proportions in tumor and normal bulk tissues were
assessed by ﬂow cytometry among CD45−CD34−CD20−CD14 (Lin−)
cells using the MSC phenotyping kit (Miltenyi Biotec Cat# 130-095-
198) (see Supplemental Experimental Procedures). N- and T-MSCs
were obtained after mechanical and enzymatic tissue disruption in
IMDM (Gibco) supplemented with Collagenase II and IV (0,5 mg/ml,
Gibco) and DNAse (0,1 mg/ml, Roche) for 2 h at 37 °C and passed
through a 100 μm cell strainer. The resulting single cell bulk was cul-
tured one night in MSC medium: IMDM+ GlutaMAX (Gibco) supple-
mented with 10% fetal bovine serum (FBS) (PAN Biotech), 1%
penicillin streptomycin (PS, Gibco), 1% non-essential amino acids
(NEAA, Gibco) and 10 ng/ml platelet derived growth factor (PDGF,
Prospec). The following day, the whole medium was changed and
only adherent cells were kept. When reaching 80% conﬂuence, cells
were split 1:4–1:6 using trypsin-EDTA 0.25 mg/ml (Lonza, USA) and
kept in culture in MSC medium. MSCs phenotype was analyzed by
ﬂow cytometry using anti-human CD90-FITC (Fluorescein isothiocya-
nate; Milteny Biotec Cat# 130-095-198), CD166-PerCP-Cy5.5 (Peridinin
Chlorophyll Protein Complex Cyanine; BD Pharmingen Cat#562131),
CD105-PE (Phycoerythrin; Milteny Cat# 130-095-198), CD73-APC
(Allophycocyanin; Milteny Biotec Cat# 130-095-198), CD44-APC-H7
(BD Pharmingen Cat#560532), CD45-AlexaFluor700 (BD Pharmingen
Cat#560566) antibodies and vimentin (Dako #M0725) and alpha-
SMA (Abcam #ab5694) expression by immunohistochemistry (IHC)
(for detailed information see Suppl. Exp. Procedures). The differentia-
tion potential in adipocytes, osteocytes and chondrocytes was assessed
(see Suppl. Exp. Procedures). BM-MSCs were isolated from the iliac
crest of 3 healthy donors (Fig. S1C; project authorization n° 131/12)Tumor stagef Neoadjuvant Gender Age
pT2b N0 Mx No F 79
pT3 N1 NAg F 58
pT2a N0 No M 62
pT4 N2 No M 64
pT2a pN0 No F 64
pT2b N1 Mx No M 68
pT3 pN0 Mx No M 70
pT1b pN0 No F 75
pT2a pN0 No M 74
pT2a pN0 No M 84
tastasis; x: not assessed histologically.
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sage 2 and 9.
2.1.2. Tumor Cells
Primary tumor cells frompatients 21, 26, 32were obtained culturing
single cell tumor bulk as spheres in ultra-low attachment ﬂasks
(Corning, Falcon) in KO medium: IMDM+ GlutaMAX completed with
20% knockout serum (Gibco), 20 ng/ml leukemia inhibitory factor
(LIF) (Prospec), 20 ng/ml recombinant human (rh) epidermal growth
factor (EGF) (Prospec), 20 ng/ml ﬁbroblast growth factor (FGF)
(Prospec) and PS 1%. The clonogenic potential was assessed as well as
the expression of tumor markers expressed by parental tumors (see
Suppl. Exp. Procedures).
2.2. Xenotransplants and Metastasis Quantiﬁcation
2.2.1. Cell Injection
Experimental protocols involvingmicewere approved by the Veter-
inary Service of the Canton of Vaud (Etat de Vaud, Service Vétérinaire),
under authorization number VD2488.1. For all experiments sphere-
forming tumor cells were injected as single cell beneath the renal cap-
sule (left kidney) of NOD-SCID- common-γ-KO (NSG) mice. All mice
were females 4–7 week old at the time of injection. Each injection was
performedusing aHamilton syringe in 20 μl of volume and cell numbers
are reported in Fig. S1E. Mice were sacriﬁced when tumors reached
1 cm3 or when the animals showed signs of distress. Otherwise they
were observed for six months after injection. Tumors were weighed
and ﬁxed in PFA 4%. Organs (spleen, right kidney, lung and liver) were
ﬁxed and parafﬁn embedded (Leica ASP200S) for subsequent metasta-
sis quantiﬁcation.
2.2.2. Metastasis Quantiﬁcation
Metastases were quantiﬁed on 3 μm thick coronal organ sections
stained with hematoxylin and eosin (HE). Images of organ slices were
then acquired by the NanoZoomer Digital Pathology slide scanner
(NDP, Hamamatsu) and metastases analyzed by imaging in a blind
manner using the NDP.view2 software. Areas ofmanually drawn circles
around organs and metastasis (as shown in Fig. S2A) were automati-
cally calculated by the software and data exported in .csv Excel ﬁles.
For each organ, the proportion (%) of the total metastatic area was cal-
culated as: (total metastatic area) ∗ 100 / (total organ area). For each
mouse, the percentage of the total metastatic area was assessed as:
(sum of the total organ (spleen + lung + kidney + liver) metastatic
areas) ∗ 100 / (sum of the total organ areas). Numbers of individual me-
tastases were also counted and expressed as the number of metastases
per organ or as a sum of the four organs. The proportion of mice bearing
0, 1–2 or 3–4 metastatic organs was calculated within each group.
2.2.3. Assessment of Primary Cell Tumorigenic Potential
Tumor cells from patients 21, 26 and 32 were ﬁrst injected alone
(n = 3 mice/patient sample) in growth factor-reduced (GFR)
matrigel (Becton Dickinson AG) to assess their tumorigenicity. To
exclude the presence of tumor contaminating cells, T-MSCs from pa-
tients 21, 26 and 32 were injected alone (n= 3mice/patient sample)
at high numbers (Fig. S1E) in GFR-matrigel.
2.2.4. Tumor Cell Co-injection With Primary MSCs
For co-injection experiments, primary tumor cells were injected
with MSCs in IMDM at a 1:1 ratio in the numbers reported in Fig. S1E.
For 21 and 32 tumor cell co-injection with MSCs, 2 independent exper-
iments were performed that gave similar results and allowed us to pool
the data together. In total, for tumor 21, 11 mice were injected in the
“control” group (ctrl, tumor cells alone), 5 mice in “+BM-MSC” group,
14mice in “+T-MSC” groups and 15mice in “+N-MSC” (corresponding
to tumor cells co-injected with BM-, T- or N-MSCs respectively). For
tumor 26, 3 mice per group were injected; however, 1 mouse in“+BM-MSC” group died for unrelated reasons and was excluded from
the study. For tumor 32, 14 mice were injected in total in the “ctrl”
group, 5 mice in the “+BM-MSC” group, 14 mice in the “+T-MSC”
group and 15 mice in the “+N-MSC” group. Mice without tumors
(n = 3: 1x21 + BM-MSC, 1x32ctrl, 1x32 + N-MSC) were excluded
from all analyses and graphs but included in the tumorigenic poten-
tial count reported in Fig. 2.
2.2.5. Tumor Cell Co-injection With Engineered-MSCs
In the 26 tumor cell/engineered-MSCs co-injection experiment,
2000 tumor cells were injected at a 1:1 ratio with the total number of
MSCs: N- or T-MSCs expressing only the Emerald reporter gene (N-
MSCEM and T-MSCEM, respectively), or a bulk of N-MSCs overexpressing
either GREM1, LOXL2, ITGA11 or ADAMTS12 (500 cells of each; N-
MSCGAIL). 6 mice were injected with 26 tumor cells +N-MSCEM cells, 7
mice with 26 tumor cells +N-MSCGAIL cells and 7 mice with 26 tumor
cells +T-MSCEM cells. In this experiment, tumor growth was also mon-
itored by ultrasound imaging. See “N-MSC overexpression of selected
genes” section for more details about engineered cell preparation.
2.2.6. Ultrasound Imaging
Tumor volume was calculated by V=4/3 p(Dd × Ds × Dt)/8, where
Dd corresponds to tumor height, and Ds and Dt to tumor lengths mea-
sured in long- and short-axis views, respectively.
2.3. MSC Expression Proﬁle Analysis by Microarray
Total RNA was extracted fromMSC samples between passage 5 and
6 using TRIzol reagent (Ambion, Life Technologies, USA) and following
standard manufacturer protocol. Affymetrix Human Gene 1.0 ST arrays
was used to compare the gene expression proﬁle between N- and T-
MSCs. Detailed information on technical procedure are reported in
Suppl. Exp. Procedures. Background correction, normalization, and
probe summarization were done using the Robust Multichip Average
(RMA) Method implemented in the Expression Console software Ver-
sion (v) 1.4.1 (Affymetrix). Filtering, hierarchical clustering (HCL), prin-
cipal component analysis (PCA), and statistical analysis of log2
transformed expression data were conducted using the Qlucore Omics
Explorer v 3.0 (Qlucore AB, Lund, Sweden). For PCA based on Pearson
correlation matrix, the data were normalized through the settings
mean = 0 and σ= 1 and variance ﬁltered on the basis of the ratio σ/
σmax. HCL was conducted on the basis of Euclidean distance (samples)
and Pearson correlation (genes). Variables were collapsed (only unique
gene symbols) and calculated as average gene expression value. Before
the downstream analyses, the following probe collections were re-
moved from the normalized data; miR BASE, Ensembl ncrna, ChrM
and ChrUn. Data were pre-ﬁltered with a ﬁxed variance ﬁlter of 0.128
(σ/σmax) giving a projection score 0.41, with a good representation of
the data. These settings captured 70% of the total variance of the dataset
(compared to a random dataset of the same size) by 3926/19260 vari-
ables. Differentially expressed genes were identiﬁed using correlation-
matrix based PCA in combination with paired t-test with eliminating
factor the patient id number and q-value (false discovery rate, FDR)
cut-off 0.2. The Benjamini–Hochberg method (Benjamini and
Hochberg, 1995) was used for error correction (q-value calculation).
2.4. RNA Extraction, cDNA Synthesis and qRT-PCR
For microarray validation, total RNA was extracted from MSC sam-
ples using TRIzol reagent. For N-MSC co-culturewith tumor cells and cy-
tokine treatment, total RNA was extracted using the RNeasy mini Kit
(Qiagen), following the standard manufacturer protocol. For each sam-
ple, cDNA was synthesized by reverse transcription using M-MLV Re-
verse Transcriptase (Promega) according to manufacturer instructions.
Levels of gene expression were determined using the 2-ΔΔCT methods
(Livak and Schmittgen, 2001) and samples analyzed in triplicates.
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versal PCR mastermix or SYBR® Green mix (Applied Biosystems).
SYBR® Green primer sequences for the quantiﬁcation of ADAMTS12,
BST2, CHI3L1, FIGF, GJA1, GREM1, IFITIM, IL6, ITGA11, LOX, LOXL2 and
MX2 are listed in the table on Suppl. Exp. Procedures section. PP1A (pro-
tein phosphatase 1; Applied Biosystems, Hs99999904_m1), 18s (Ap-
plied Biosystems, Hs99999901_s1), GAPDH or TBP (SYBR® Green)
were used as housekeeping genes. For microarray validation, for each
patient, data were normalized on N-MSC expression levels (fold
change= 1). For BM-MSC comparisonwith N- and T-MSC gene expres-
sion levels, data were normalized on expression levels of N-MSCs from
patient 12 (fold change = 1). For N-MSC co-cultures with tumor cells
or treatment by cytokines, expression levels were normalized on N-
MSCs cultured in control condition (fold change = 1).
2.5. Secretome Analysis
SecretomeofN- and T-MSCs frompatients 12 and21was assessed in
concentrated supernatants from cells cultured for 24h in IMDMwithout
phenol red supplemented with PS1% and PDGF 10 ng/ml. Samples were
concentrated, digested with trypsin and analyzed on a high resolution
hybrid LTQ Orbitrap Velosmass spectrometer (Thermo Fisher Scientiﬁc,
Bremen, Germany) coupled to a nano-liquid chromatography system.
Repeated analysis of 21N- and 21T-MSC secretomes together with
BM1 and BM3 samples (Fig. S3B) were prepared and processed simi-
larly, with the only difference that MS analysis was done on a Fusion
Tribrid Orbitrap instrument (Thermo Fisher Scientiﬁc, Bremen,
Germany). More details on sample preparation and analysis can be
found in Suppl. Exp. Procedures.
2.6. N-MSC Expression Analysis After Tumor Cell Co-culture and Cytokine
Treatment
2.6.1. Co-culture
N-MSCs and tumor cells from patients 21, 26 and 32 were co-
cultured in transwell conditions at different N-MSC:tumor cell ratios:
2:1, 1:1, 1:2 and 1:5. Co-cultures were analyzed after 3, 5 and 7 days.
N-MSCs (20.000 cells/well) were seeded at passage 5 onto six-well
plates (Costar, Corning incorporated). Tumor cells were seeded into
1,0 μm-pore insert of PET-membrane (Corning, Falcon) at different
amounts according to the four different ratios. Controls were T- and
N-MSCs cultured alone.
2.6.2. TGF-β1 and IL-6 Treatment
21, 26 and 32 N-MSCs (20.000 cells/well) were seeded in six-well
plates and treated for 3, 5 and 7 days either with IL-6 (10 ng/ml,
Sigma), TGF-β1 (1 ng/ml or 10 ng/ml, Miltenyi Biotec) or a combination
of the two in MSC medium. Controls were untreated N-MSCs.
2.6.3. Co-culture in Presence of TGF-β1 Treatment
N-MSCs and tumor cells from patients 21, 26 and 32 were co-
cultured in transwell conditions as described above at 1:1 and 1:5 N-
MSC:tumor cell ratios in the presence of TGF-β1 10 ng/ml. Co-cultures
were analyzed after 3, 5 and 7 days. Controls were N-MSCs cultured
alone in absence of TGF-β1.
For all experiments, cells were cultured in MSC medium, half of
which was refreshed at days 3 and 5. At the end of co-culture or treat-
ment, N-MSCs were harvested, snap frozen and stored at -80 °C until
RNAextraction. Gene expressionwas assessed by qRT-PCR as previously
described and data normalized to corresponding expression levels in N-
MSCs cultured alone and/or untreated (fold change = 1).
2.7. 3D Spheroid Invasion Assay
Tumor cells from patients 21, 26 and 32were stained with CellTrace
CFSE 10 μm (Carboxyﬂuorescein succinimidyl ester; Molecular Probes;Cat# C34554) according to the manufacturer's instructions. CFSE-
labeled tumor cells (2500 cells/45 μl drop) were cultured in hanging
drop plates (HDP Perfecta3D 96-Well Hanging Drop Plates; 3D
Biomatrix) according to the manufacturer's instructions for 60 h in the
presence or absence of paired N- or T-MSCs at a 1:1 MSC:tumor cell
ratio to allow spheroid formations. N- and T-MSCs alone
(2500 cells/45 μl drop) were cultured under the same conditions and
used as supplemental controls for MSC migration. All conditions were
performed in quadruplicate. After 60 h, spheroids were transferred by
centrifugation (5 min, 180 g, at 4 °C) to a 96-well U-bottom (TPP)
plate ﬁlledwith pre-chilled invasionmatrix 50 μl/well (Cultrex Invasion
Matrix; Amsbio; Cat# 3500-096-03) according to themanufacturer's in-
structions. The 96-well U-bottom plates containing the spheroids were
then incubated for 1 h at 37 °C to promote polymerization of thematrix.
After polymerization, 100 μl/well of KOmediumwere added and plates
kept at 37 °C for 4 days. Mediumwas refreshed at 48 h by adding 50 μl/
well of KO medium. For each spheroid, images were taken by light and
ﬂuorescentmicroscopy at day 0 and every 24h thereafter using a 4×ob-
jective. Lighting and focus were adjusted to provide maximal contrast
between the 3D structure and background.2.8. Tumor Cell Co-cultures With MSCs and RNA Sequencing
2.8.1. Co-culture
21 and 32 tumors were dissociated to single cells and seeded onto
ultra-low attachment six well plates (Costar, Corning) at 50.000 cells/
well and maintained in transwell culture for 5 days with paired N- or
T-MSCs at a 1:1 tumor:MSC cell ratio. For both tumor cell types, a second
independent experiment was performed using 29 MSCs. MSCs were
seeded into 1,0 μm-pore inserts of PET-membrane (Corning, Falcon).
Controls were tumor cells cultured alone. Cells were cultured in KOme-
dium, half of which was refreshed at day 3. After removal of the upper
chamber containing MSC cells, tumor cells were harvested, snap frozen
and stored at -80°C until RNA extraction with miRCURY RNA isolation
kit (Exiqon) following manufacturer instructions including a DNAse
step with RNAse-Free DNase set (QIAGEN). RNA was stored at -80°C
until RNA-seq analysis.2.8.2. RNA-seq Analysis
The TruSeq mRNA stranded kit from Illumina was used for the li-
brary preparation. Pools of 6 libraries were loaded at 8.5 pM for cluster-
ing on a Single-read Illumina Flow cell. Reads of 100 bases were
generated using the TruSeq SBS HS v3 chemistry on an Illumina HiSeq
2500 sequencer. PCA analysis was donewith R v3.3.2 using limma pack-
age to remove batch and sample effects and stats package for the analy-
sis. The differential expression analysis was performed with edgeR
v3.10.5. The differentially expressed genes were deﬁned as those with
P-value b 0.05, fold change (FC) N 2 and detectable expression. Gene on-
tology analysis was performed using GSEA software and Molecular Sig-
nature Database (MSigDB) (Subramanian et al., 2005), http://software.
broadinstitute.org/gsea/index.jsp. For more detailed information, see
Suppl. Exp. Procedures.2.9. Transwell Invasion Assay
Transwell (TW) invasion of CFSE-labeled tumor cells from patients
21 and 32 was assessed through a matrigel-coated membrane in re-
sponse to different culture conditions: the presence of N- or T-MSCs
(in IMDM-FBS 10%) in the lower invasion chamber or of IMDMmedium
supplemented or not with 10% FBS. After overnight culture, images of
invading tumor cells were taken in the lower chamber and on themem-
brane by light and ﬂuorescent microscopy using a 4× objective. For
more detailed information, see Suppl. Exp. Procedures.
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2.10.1. MSC Differentiation and IHC Assays
Images were taken with a Nikon Eclipse E800 digital camera
DXM1200with a resolution of 1280× 1024 at 20× or 40×magniﬁcation
and analyzed with the ACT-1 (v.2) software
2.10.2. Spheroid and TW Invasion Assays
Images were taken with a Olympus IX53, digital camera U-HGLGPS,
with a resolution of at 4×magniﬁcation, and analyzed with the cellSens
Entry (v1.13) Olympus software.
2.11. N-MSC Overexpression of Selected Genes
First, we cloned the Emerald (EM) gene (Invitrogen) into a lentiviral
plasmid (pLIV) derived from the pLVTH backbone (addgene) to express
the puromycin resistance gene (Puro-r). GREM1, LOXL2, ADAMTS12 and
ITGA11 geneswere then cloned in the resulting pLIV_Puro_2A_Emback-
bone. Detailed information about cloning, virus production and titration
are reported in Suppl. Exp. Procedures.
N- and T-MSCs from patient 26 were infected at passage 5 by two
rounds of infection using Polybreen 8 ng/ml (Sigma) with an overnight
pause in MSCmedium and at a 0.5MOI (multiplicity of infection). Anti-
biotic selection (Puromycin, 2 μg/ml) was added 48 h after the second
infection and kept for 4 days. N-MSCswere infected eitherwith EM con-
trol virus (N-MSCEM) or with single-gene overexpressing viruses. For
mice injection, equal numbers (1/4 each) of single-gene overexpressing
N-MSCswere taken and injected as a bulk (N-MSCGAIL). T-MSCswere in-
fected only with EM control virus (T-MSCEM). Gene overexpression was
assessed by qRT-PCR and cells taken formice injection at passage 3 after
infection.
2.12. Statistical Analysis
Statistical tests and graphics were generated by Prism version 7.03
(GraphPad Software Inc.). Nonparametric paired Wilcoxon test was
used to compare percentages of MSCs in normal and tumor tissue (*, P
≤ 0.05). For mouse injections, tumor weights andmetastasis quantiﬁca-
tionwere analyzed using the nonparametric Kruskal–Wallis (K–W) test
with Dunn's multiple comparison test to compare each group (tumor
cells co-injected with MSCs) with the control group (tumor cells
alone). For 26 tumor cell co-injection with engineered MSCs, 26 tumor
cells injected with N-MSCEM were considered as control group. When
signiﬁcant, adjusted p-values from Dunn's test were reported in the ﬁg-
ure and indicated in the graphs as * or ** according with their degree of
signiﬁcance (**, P ≤ 0.01). The correlation between total number of me-
tastasis and metastatic area was assessed using non parametric Spear-
man correlation test: r and P-values are reported on the graphs. For
qRT-PCR data for microarray validation, multiple t tests were used to
comparemedian expression levels between N- and T-MSCs for each pa-
tient. Gene expression levels between BM-, N- and T-MSCs were com-
pared using the nonparametric Kruskal-Wallis (K-W) test with Dunn's
multiple comparison test. For N-MSC co-cultures with tumor cells and
treatment by cytokines, multiple t tests were used to compare each
group to N-MSC control group. Signiﬁcant differences were indicated
as *, **, *** or **** according to level of signiﬁcance (***, P ≤ 0.001; ****,
P ≤ 0.0001). Not signiﬁcant P-values (P b 0.1) were reported and indi-
cated as “ns” (not signiﬁcant).
2.13. Accession Numbers
The array data are deposited in the NCBI Gene Expression Omnibus
(GEO) database and accessible through the series accession number
GSE104636. RNA-Seq data have been deposited in the NCBI Gene Ex-
pression Omnibus (GEO) database and accessible through the series ac-
cession number GSE104858.3. Results
3.1. Characterization of MSCs and Primary Tumor Cells From Patients With
Lung Carcinoma
Freshly removed untreated primary lung cancer samples andnormal
adjacent tissues were collected from ten patients diagnosed with SCLC
(n = 2), AC (n = 3) or SCC (n = 5) at different stages of progression
(pT1bN0-pT4N2) but without distant metastasis (Table 1). Mesenchy-
mal stem cell content was assessed byﬂow cytometry after tissue disso-
ciation into single cells. Although their percentageswere small (ranging
from 0.007 to 4.49% among lineage-negative (Lin−) cells), MSCs were
signiﬁcantly more abundant in tumor than in normal tissues (P =
0.0156; Figs. 1A and S1A), irrespective of the tumor subtype or the
abundance of inﬂammatory and immune cell inﬁltrates (considered as
Lin+ cells, Fig. S1B). Following separation from normal and tumor tis-
sues, the T- and N- stromal cell phenotype was compared to that of
BM-MSCs from three healthy donors (BM1 to 3 aged 51, 54 and 78 re-
spectively at the time of surgery; Fig. S1C). Cell surface expression of
the MSC-associated markers, CD90, CD166, CD105, CD44 and CD73
(Dominici et al., 2006; Kobolak et al., 2016) was comparable among
the three populations of cells (Fig. 1B). Similar to BM-MSCs, N- and T-
MSCs (between passage 3 and 7 in culture) could differentiate into ad-
ipocytes, osteocytes and chondrocytes (Fig. 1C), with some variability
most likely due to patient and donor age (Mijung Kim et al., 2012a;
Stolzing et al., 2008). All MSC samples expressed vimentin but were
negative for α-SMA (Figs. 1D and S1D), indicating their distinction
from myoﬁbroblasts (Kalluri, 2016; Öhlund et al., 2014). Tumor cell
presence among the MSCs was excluded by verifying that their karyo-
type was normal (data not shown) and that even high numbers (rang-
ing from100000 to 300000 cells permouse) of T-MSCs injected beneath
the renal capsule of NSG mice failed to generate tumors after a six
month follow-up (Fig. S1E).
Bulk tumor cell culture in low-adherence conditions in the absence
of serum, allowed isolation and expansion of primary tumor cells from
two patients (21 and 32) diagnosed with poorly differentiated SCC
and one patient (26) with a composite tumor with a 60% SCLC compo-
nent (Table 1). Tumor cells and paired MSCs will be referred to accord-
ing to the numbers attributed to the patient samples (21, 26 and 32)
they were derived from. Tumor cells were cultured as spheres and
assessed for conservation of parental tumor markers. Consistent with
their SCC identity, 21 and 32 spheres were positive for p63 and negative
for TTF-1 (Gurda et al., 2015; Kalhor et al., 2006; Noh and Shim, 2012)
(Fig. 1E). Spheres from tumor 26 were positive for chromogranin A
(CgA) and TTF-1 expression (Van Meerbeeck et al., 2011), reﬂecting
the SCLC/neuroendocrine phenotype of their tumor of origin (Fig. 1E).
To assess their self-renewal, spheres were dissociated, plated as single
cells and monitored for colony formation (Fig. S1F). Cells from the
three tumors displayed comparable clonogenic potentialwithmean for-
mation of 29.9, 30.3 and 25.3 spheres/100 wells by cells from patients
21, 26 and 32, respectively. Injection of low cell numbers (ranging
from 1000 to 5000 cells per mouse; Fig. S1E) from all three cultures be-
neath the renal capsule of NSG mice resulted in tumor formation but
with different kinetics, requiring subsequent adjustment of the number
of cells injected to synchronize tumor engraftment (Fig. S1E). Successful
isolation, of primary lung MSCs along with the corresponding lung can-
cer cells from three patients, provided us with unprecedentedmeans to
probe the functional relationship between MSCs and autologous cancer
cells.
3.2. T-MSCs Enhance Metastasis of Paired Primary Cancer Cells
To address the effect of primary tumor-associated MSCs on tumor
progression, we compared tumor formation resulting from co-
injection of tumor cells and T-MSCs to that arising from co-injection of
tumor cells with unrelated BM-MSCs and injection of tumor cells
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likely to have little impact on the global behavior of large primary tu-
mors, their effect on small tumor cell subpopulations within the
tumor mass with which they are in contact may be highly relevant.
Low cell numbers at a 1:1 MSC:tumor cell ratio were therefore used in
all co-injections. Tumor engraftment was comparable among the three
groups for all primary samples (Fig. 2). In contrast, a signiﬁcantly in-
creased metastatic load was observed when tumor cells from sample
21 were co-injected with paired T-MSCs (P = 0.0242), with samples
26 and 32 displaying the same trend (Fig. 2). Metastases occurred
mainly in liver, lung and spleen and in the contralateral kidney of
mice injected with cells from sample 21 (P = 0.0098; Fig. S2B). More-
over, cells from all tumor samples co-injected with T-MSCs formed
multi-organ metastases whereas their co-injection with BM-MSCs re-
sulted in a more modest metastatic spread (Fig. 2, right panels) with
the exception of the spleen, which displayed a comparable metastatic
load (Fig. S2B). These observations suggest that MSCs preferentially en-
hance dissemination of primary tumor cells rather than their tumor
forming ability at the site of injection and that although both BM- and
T-MSCs promote metastasis, T-MSCs display a more potent effect.
3.3. T-MSCs and Paired N-MSCs Display Different Gene Expression Proﬁles
Although tumor-associated MSCs may be recruited from various
sites, including the bone marrow and adipose tissues, the most likely
source are normal tissue-resident MSCs, warranting phenotypic and
functional comparison between paired T- andN-MSCs.Microarray anal-
ysis of 9 primary paired samples (the 10th sample was obtained at a
later date) indicated that T- and N-MSCs display distinct gene expres-
sion proﬁles. Using a ﬁxed variance ﬁlter 0.128 (σ/σmax) and a 0.2 q-
value (FDR) cut-off, we identiﬁed 205 differentially expressed genes
(P-value b 0.01039): 165 genes were upregulated and 40 downregu-
lated in T-MSCs (Fig. 3A). The observed gene modulation was indepen-
dent of the tumor subtype and 12 among the 50 most signiﬁcantly up-
regulated (P b 0.00252; fold changes 1.22 b x b 9.36; Table S1) genes
were selected for validation, including: MX2, CHI3L1, GREM1, LOXL2,
GJA1, ITGA11, IFITM1, BST2, ADAMTS12, LOX, FIGF and IL6 (Fig. 3B). Vali-
dation was performed on 10 pulmonary T- and N-MSC sample pairs.
With the exception of GJA1 and LOX, which were found to be signiﬁ-
cantlymore highly expressed in T-MSCs in only 5 and 4 pairs of samples
respectively, increased expression in T-MSCs of all the remaining genes
was validated in at least 7 out of 10 pairs (Fig. 3B). Nine of the genes se-
lected for initial validation were used in subsequent experiments.
BM-MSCs from three unrelated adults displayed higher LOXL2, GJA1
and ITGA11 expression than most T-MSCs whereas GREM1 and
ADAMTS12 expression was comparable in BM- and T-MSCs (Fig. S3A).
CHI3L1, BST2, IL6, MX2, IFITM1, LOX and FIGF were more weakly
expressed or undetectable in BM-MSCs, more closely resembling the
N-MSCs proﬁle (Fig. S3A). With respect to the selected panel of genes,
BM-MSCs therefore displayed a phenotype that was distinct from that
of T- and N-MSCs.
Because several of the selected genes encoded secreted proteins, we
assessed the secretome of N- and T-MSCs from two patients with SCC
(12 and 21) and of BM-MSCs from two healthy donors. Twelve proteinsFig. 1. PrimaryMSC and tumor cell characterization. (A)On the left, proportions ofMSC-like (CD
and tumor lung tissues (n = 7) assessed by ﬂow cytometry after tissue dissociation. Statistic
indicated as * according to the level of signiﬁcance (P b 0.05). On the right, dot plots and hist
living, Lin− and CD90+CD105+ cells for the assessment of MSC-like cell proportions in norm
CD73+ cells among the parental population are reported. CD73 expression by CD90+CD105+
vitro characterization of MSC cell cultures: N- and T-MSCs from lung carcinoma patients (n =
MSC surface markers was calculated by ﬂow cytometry and reported as percentages amo
adipocytes (Oil Red O), osteocytes (Von Kossa) and chondrocytes (Alcian Blue) of MSCs from
expressions were assessed immunohistochemically on BM3 and N- and T-MSCs from patie
patients were characterized for the expression of tumor markers and compared with tumors odisplayed signiﬁcantly different abundance in the supernatants (SN) of
MSCs from both patients (Fig. 3C), but only ﬁve (GREM1, LOXL2, SRGN,
THBS2 and IGF2)were increased in the SNs fromboth 12 and 21 T-MSCs
(in red). Theseﬁve secreted proteinswere also found in the conditioned
media of the two batches of BM-MSCs at levels that were higher than
(SRGN and THSB), comparable to (GREM1 and LOXL2) and lower than
(IGF2) those observed in T-MSC supernatants (Fig. S3B). LOXL2 enrich-
ment was validated by Western blot analysis of freshly prepared SNs
from N- and T-MSCs from patients 21, 26, 32, as well as from patient
29 (Fig. S3); only patient 29 samples had comparable LOXL2 levels in
N- and T-MSC SNs. Among the non-secreted proteins, assessment of
ITGA11 byWestern blot analysis revealed its expression to be increased
in all T-MSC cell lysates compared to their N-MSC counterparts (Fig. S3).
3.4. The Tumor Microenvironment Induces N-MSCs to Acquire a T-MSC Ex-
pression Proﬁle
To address the possibility that T-MSCs may originate from resi-
dent N-MSCs in response to tumor cell and TME-derived signals,
we cultured N-MSCs from patients 21, 26 and 32 in the presence of
increasing numbers of paired primary tumor cells and assessed ex-
pression of 9 validated genes at 3, 5 (not shown) and 7 days
(Figs. 4 and S4A, left columns). On day 7, the expression of 5 out of
the 9 genes was signiﬁcantly induced in N-MSCs from at least one pa-
tient proportionally to increasing tumor:MSC cell ratios. IL6 and BST2
were signiﬁcantly induced in all N-MSC samples already after 3 days,
with IL6 reaching levels comparable to those in T-MSCs. In contrast,
ADAMTS12, MX2, LOXL2 and GREM1 expression varied during the
course of the assay, often displaying transient induction in the differ-
ent N-MSC cultures. Other genes, including FIGF, ITGA11 and CHI3L1
were not induced in any of the culture conditions. Altogether, our re-
sults show that tumor cells alone can modulate the N-MSC gene ex-
pression proﬁle, but that the resulting changes only partially
recapitulate T-MSC features. Mediators generated by components
of the TME most likely contribute to the establishment of the full T-
MSC phenotype.
Inﬂammation and tissue remodeling are inherent to the TME
(Landskron et al., 2014; Shi et al., 2015), which, as a consequence,
is rich in a wide range of cytokines. A key cytokine in tissue repair
is transforming growth factor β (TGF-β), which orchestrates
wound healing and has a dual effect on cancer, displaying both
tumor suppressive and tumor enhancing properties, depending on
the context and stage of tumor progression (Ikushima and
Miyazono, 2010). TGF-β was expressed comparably in the tumor
cells and MSCs, as assessed by qRT-PCR (Fig. S4B) but unlike N-
and T-MSCs, tumor cells did not secrete detectable levels of TGF-
β1 (Fig. S4B). Using Cytoscape software for the analysis of molecu-
lar interactions and pathway connectivity, we found that TGF-β1
could be potentially connected to proteins encoded by several of
the genes found to be upregulated in T-MSCs, especially IL6
(Fig. S4C). We therefore subjected N-MSCs (21, 26 and 32) to both
cytokines and assessed the changes in the N-MSC phenotype at 3,
5 (data not shown) and 7 days of treatment with each. Whereas sig-
niﬁcant IL-6-mediated induction of expression of the selected genes105+CD90+CD73+) cells among Lin− cells (CD45−CD34−CD20−CD14−) in paired normal
al signiﬁcance was determined by Wilcoxon matched-pairs signed rank test; P-value is
ograms from one representative patient (21) depicting the sequential gating strategy on
al and tumor tissues. Percentages of Lin−, CD90 and CD105 double positive cells, and
cells (blue) was calculated using unstained living cells as negative control (red). (B–D) In
10) were compared with BM-MSCs from healthy donors (n = 3). (B) The expression of
ng living cells. Horizontal lines represent medians. (C) Differentiation potential into
one representative donor (BM1) and patients 21 and 29. (D) Vimentin and alpha-SMA
nt 21, 26 and 32. (E) Sphere-forming tumor cells (right pictures) from 21, 32 and 26
f origin (left pictures). (C–E) Scale bar = 50 μm. See also Fig. S1.
Fig. 2. T-MSCs promote themetastatic potential of paired primary lung cancer cells more efﬁciently than BM-MSCs. Results frommouse injectionswith 21, 26 and 32 primary tumor cells
alone (CTRL) or in the presence of BM-MSCs (from one healthy donor, BM1) or paired T-MSCs. For 21 and 32 tumors, 2 independent experiments were performed and data pooled
together. Numbers of total injected mice per group are indicated as the denominator for the assessment of tumorigenicity. For each group, the tumorigenic ability is reported as the
ratio between the number of mice with tumors to the total number of injected mice. Mice without tumors (n = 2) were not included in analyses or graphs. Tumor weights (grams,
(g); left panels), percentages of total metastatic area per mouse (middle panels) and proportions of mice per group with 0 (white bars), 1–2 (clear blue) or 3–4 (dark blue) metastatic
organs (right panels) are depicted for the three groups. Horizontal lines represent mean values. Groups were compared using the nonparametric Kruskal–Wallis (K–W) test with post-
hoc Dunn's multiple comparison test. Signiﬁcant differences are reported as *according to the level of signiﬁcance (P b 0.5). See also Fig. S2.
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β1 enhanced the expression of multiple genes (Figs. 4 and S4A, mid-
dle columns). ITGA11 and FIGF were the most signiﬁcantly up-
regulated genes in 21 and 26 N-MSC samples, reaching levels com-
parable to those observed in T-MSCs (Figs. 4A and S4A). GREM1,
ADAMTS12 and LOXL2 were upregulated only in N-MSCs from pa-
tient 26 and IL6 only in patient 21 N-MSCs after 7 days of treatment
whereas TGF-β1 had no signiﬁcant enhancing effect on BST2, MX2
or CHI3L1 expression. Combined treatment using the two cytokines
recapitulated the effect of TGF-β1 alone (not shown). Addition of
TGF-β to tumor cell-N-MSC co-culture augmented MX2, BST2 andFig. 3. Comparison between primary samples of paired N- and T-MSCs. (A-B) Comparison betw
patients. (A)Microarray heatmap showing a distinctmRNA expression proﬁle between paired s
genes are depicted in yellow, down-regulated genes in blue. Each column represents aMSC sam
genes identiﬁed by symbols on the right of the heatmap. Dendrograms are based on hierarchica
genes. Samples are ordered according to tumor subtype (SCC, AC or SCLC) and patient ID are
normalized to N-MSC levels using the PP1A housekeeping gene. Median values and SD fro
multiple t tests. Signiﬁcant differences were indicated according to the level of signiﬁcance:
paired N- and T-MSC samples from patients 12 and 21. In red, proteins found to be signiﬁca
different abundance in the two samples but in opposite direction. Squares represent signiﬁc
Fig. S3 and Table S1. (For interpretation of the references to color in this ﬁgure legend, the reaIL6 (Figs. 4 and S4A, right columns) but not ADAMTS12, LOXL2
GREM1 or CHI3L1 expression in N-MSCs. At a 5:1 tumor cell-N-MSC
ratio, tumor cell presence appeared to attenuate ITGA11 upregula-
tion by TGF-β in sample 21 N-MSCs (Fig. 4, right column). Con-
versely, TGF-β abrogated tumor cell-co-culture-dependent
augmentation of LOXL2 and ADAMTS12 expression in patient 21 N-
MSCs (Fig. 4, right column). Thus, TGF-βmodulation of the N-MSC phe-
notype may be affected by tumor cell presence and may in turn alter
the effect of tumor cells on MSCs in a manner that cannot be readily
predicted. These observations underscore the complexity of tumor
cell-TME interplay in shaping host tissue stromal behavior.een the expression proﬁle of N- (black) and T-MSC (grey) samples isolated from the same
amples from 9 patients. Log2 expression values are indicated by a color scale: up-regulated
ple (patient identiﬁcation numbers (ID) are reported at the bottom)while rows represent
l clustering of samples/variables. (B) Validation by quantitative Real-Time PCR of selected
indicated below each graph. For all genes and for each patient (n = 10), expression was
m triplicates are shown. Paired N- and T-MSC expression levels were compared using
* at P ≤ 0.05; ** at P ≤ 0.01; *** at P ≤ 0.001; **** at P ≤ 0.0001. (C) Secretome analysis of
ntly up-regulated in both T-MSC samples. In blue, proteins found to have signiﬁcantly
ant differentially secreted proteins from patient 12, triangles from patient 21. See also
der is referred to the web version of this article.)
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137G. Fregni et al. / EBioMedicine 29 (2018) 128–1453.5. N- and T-MSCs PromoteMetastases of Paired Tumor Cells and Promote
Tumor Cell Dissemination in 3D Gels
Based on our observations that primary tumor cells can modulate
the phenotype of N-MSCs in vitro, it would seem reasonable to expect
mutual modulation of behavior between MSCs and tumor cells. N-
MSCs « educated » by the tumor cells and the TME to become T-MSCs
may thus signal back to the tumor to support progression of some of
its cell subpopulations. We therefore co-injected 21, 26 and 32 primary
tumor cells with N-MSCs from the same patients and assessed tumor
growth and dissemination. Whereas we did not observe any difference
in tumor weight at the site of injection (data not shown) the two SCC
tumor samples (21 and 32) co-injected with N-MSCs displayed higher
metastatic activity, similar to that resulting from co-injection with T-
MSCs (Figs. 2, 5A and S5B). The number of mice bearing metastases in
multiple organs increased in both 21 and 32 tumor cell co-injections
with N-MSCs compared to injection of tumor cells alone. In fact, 32 N-
MSCs induced higher metastatic activity of the paired tumor cells than
the corresponding T-MSCs (Fig. 5A). The total number of metastases
correlated with metastatic tumor size (Fig. S5A). N-MSCs promoted
tumor 21 and 32 metastases to the liver and spleen, as well as the kid-
ney for tumor 21 (Fig. S5B). In contrast, co-injection of the composite
carcinoma 26 tumor cells with paired N-MSCs failed to enhance their
metastatic activity (Figs. 5A and S5B). The inﬂuence of tumor cells in
N-MSC transition to the T-MSC phenotypemay therefore vary according
to tumor cell properties. In some cases, the T-MSC phenotype may be
primarily sculpted by the TME, which may display at least some com-
mon features among different tumor types. Consistent with this notion
SCC- and composite tumor-derivedMSCs had a similar transcriptome. It
is also noteworthy that T-MSCs maintain their phenotype in culture, at
least for the number of passages to which they were subjected in the
present study, indicating that the phenotype is stable, and not depen-
dent on continued tumor cell presence.
To determine whether MSCs may directly inﬂuence tumor cell mi-
gration, we assessed tumor cell detachment from spheroids in the pres-
ence and absence of MSCs in 3D gel culture. Tumor spheroid co-culture
with T-MSCs in 3D gels revealed progressive individual tumor cell de-
tachment from spheroids along the path of MSC spreading (Figs. 5B
and S6), suggesting that MSCs may physically facilitate tumor cell dis-
semination. Spheroid cultures in the absence of MSCs remained com-
pact without signiﬁcant cell detachment (Figs. 5B and S6). One
mechanism by which MSC may promote tumor dissemination may
therefore be the creation of a path for tumor cells to travel along, possi-
bly led by migrating MSCs.
3.6. N- and T-MSCs Induce Similar Gene Expression Changes in Tumor Cells
To further explore mechanisms by which MSCs may enhance dis-
semination of paired tumor cells, we addressed, by RNA-Seq, the
changes in the gene expression proﬁle of tumor cells induced by co-
culture with lung MSCs. Based on their comparable histology and their
similar behavior in vivo, we focused on samples 21 and 32. To address
the general applicability of the effect of MSCs on SCC progression, we
also co-cultured the tumor cells with unrelated T- and N-MSCs derivedFig. 4.N-MSC phenotype ismodulated by different components of the tumormicroenvironmen
bars) or with increasing numbers (green color scale bars) of primary tumor cells from the sa
indicated. The indicated gene expression was assessed by qRT-PCR and normalized to N-MS
cultured under the same conditions (red bars) are shown as a reference. Data represent m
compared with T-MSCs or with N-MSCs in presence of the lowest or the highest number of
(light blue bars) or 10 ng/ml (dark blue bars). Gene expression levels normalized to untreated
Median values and SD from triplicates are shown. (Right column) N-MSCs from patients 21,
the same patient at 1:1 (light green bars with black dots) or 1:5 (dark green bars with black
reported genes was assessed by qRT-PCR and normalized to untreated N-MSCs cultured al
triplicate assays are shown. For all experiments, gene expression levels were compared by m
comparisons of N-MSCs alone and/or untreated with N-MSCs cultured in other conditions a
0.001; **** at P ≤ 0.0001. When almost signiﬁcant (P ≤ 0.1), P-values are also reported with thefrom patient 29. The PCA plot of RNA-Seq data showed similar results
when each of the tumor cell batcheswas culturedwith paired or sample
29MSCs. The similaritywas particularlymarkedwhen sample 32 tumor
cells were used (Fig. 6A). Thus, in subsequent analyses they were con-
sidered as replicates and data were pooled together. Principal compo-
nent 1 (PC1) revealed that tumor cells cultured alone (green symbols)
display amarkedly distinct transcriptome from the same cells following
indirect co-culture with MSCs (blue and red symbols; Fig. 6A). In con-
trast and mirroring the results obtained from in vivo experiments, vari-
ation between tumor cell transcriptomes following co-culture with N-
or T-MSCs was far more limited, precluding differential clustering of
samples according to the two co-culture conditions. As a result, we ob-
served a highly signiﬁcant overlap among genes modulated (P-value b
0.05, fold change N 2 and detectable expression) in tumor cells by expo-
sure to N- or T-MSCs (Fig. 6B and Table S2), consistent with the obser-
vation that tumors contribute to N-MSC acquisition of a T-MSC
phenotype. Substantial variation in terms of gene expression changes
was observed between the two tumors upon exposure to MSCs
(Fig. 6B and Table S2), possibly explaining the differences in metastatic
number and volume induced byMSCs (Fig. 5A). Similarly, the number of
genesmodulated by T- andN-MSCs differed and in 32 tumor cells, more
genes were modulated by N- than by T-MSCs (Fig. 6B and Table S2). As
expected, some genes were modulated in both 21 and 32 tumors fol-
lowing N- or T-MSC co-culture. Thus, KALRN was downregulated in all
settings, whereas 6 upregulated genes were shared among 21 + N-
MSC, 21 + T-MSC and 32 + N-MSC co-cultures, including CD180,
GDF15, PLEKHB1, TGM2, VEGFA and ZNF385A. Some of these genes are
reported to be associated with epithelial-mesenchymal-transition
(EMT) and hypoxia, both of which are implicated in metastasis (Gilkes
et al., 2014; Lu and Kang, 2010; Tsai and Yang, 2013). Gene ontology
(GO) analysis of the 52 genes upregulated in 21 tumor cells following
both N- and T-MSC co-culture further showed signiﬁcant enrichment
in genes related to EMT and hypoxia (Fig. 6C). Interestingly, the most
signiﬁcantly overrepresented GO term included genes related to the
placenta, recently reported to be associated with aggressive,
metastasis-prone lung cancer (Rousseaux et al., 2013). Altogether, our
co-culture experiments indicate that primary MSCs can modulate the
expression proﬁle of paired lung cancer cells, inducing genes that are as-
sociated with an aggressive tumor phenotype and possibly explaining
their increased metastatic potential in vivo.
To determine whether the observed changes in the tumor cell tran-
scriptome may correlate with enhanced invasiveness, we assessed pa-
tient 21 and 32 tumor cell behavior in transwell assays in the
presence and absence of N- and T-MSCs. MSCswere cultured in the bot-
tom chamber in the presence of serum, whereas CFSE-labeled tumor
cells were seeded onto matrigel in the top chamber in the absence of
serum. Tumor cell migrationwas scored following overnight incubation
after removal of cells that had remained on the surface of the gel. Fluo-
rescent cells were counted in the lower chamber (Fig. 6D, lower panel)
and were also visualized on the transwell membrane (Fig. 6D, upper
panel). Both N- and T-MSCs promoted invasion of the gel and penetra-
tion into the lower chamber of sample 21 tumor cells (Fig. 6D, lower
panel). Cells from tumor 32 displayed enhanced entry into thematrigel
in response to N-MSCs, as assessed by ﬂuorescence on the transwellt. (Left column) N-MSCs from patients 21, 26 and 32were cultured for 7 days alone (black
me patient in indirect conditions (1-μm pore size inserts); N-MSC:tumor cell ratios are
Cs cultured alone using the PP1A housekeeping gene (fold change = 1). T-MSCs alone
edian values and SD from triplicate assays. For statistical analysis, N-MSCs alone were
tumor cells. (Middle column) N-MSCs were treated for 7 days with TGF-β1 at 1 ng/ml
N-MSCs (black bars) using the TBP housekeeping gene (fold change = 1) are indicated.
26 and 32 were cultured for 7 days alone (black bars) or with primary tumor cells from
dots) N-MSC:tumor cell ratios and treated with TGF-β1 at 10 ng/ml. Expression of the
one using the TBP housekeeping gene (fold change = 1). Median values and SD from
ultiple t tests using the Holm-Sidak correction method. The adjusted P-values from the
re indicated according to the level of signiﬁcance: * at P ≤ 0.05; ** at P ≤ 0.01; *** at P ≤
symbol “ns” (not signiﬁcant). See also Fig. S4A.
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the experimental time frame.
3.7. GREM1, LOXL2, ADAMTS12 and ITGA11 Expression by MSCs Promote
Tumor Cell Metastasis
To further investigate the mechanism by which MSCs promote
tumor dissemination, we sought to identify genes whose expression
was induced inMSCs by cancer cells or the TME thatmay be functionally
implicated in promoting lung cancer metastasis. Among the genes that
were upregulated in T-MSCs, we selected GREM1 and LOXL2, whose in-
creased expression was validated by qRT-PCR and whose encoded pro-
teins were signiﬁcantly enriched in T-MSC supernatants (Fig. 3).
Interestingly, analysis of numerous gene expression datasets from
tumor samples of non-small cell lung carcinoma patients available in
the R2 genomics database, revealed that expression of these two
genes is highly correlated. Remarkably, in all tested microarrays,
GREM1 and LOXL2 were associated with the expression of two other
genes among the top 30 genes upregulated in T-MSCs (Table S1),
ADAMTS12 and ITGA11, whose increased expressionwe had already val-
idated. To further probe the putative relationship between these four
genes, we examined a microarray heatmap of genes whose expression
is strongly correlated with GREM1 from one representative dataset,
“Tumor Non-small cell lung carcinoma - Plamadeala - 410 - MAS5.0 -
u133p2” (Huang et al., 2015) (Fig. S7A). The dataset does not distin-
guish between gene expression in tumor cells and in the stroma. How-
ever, in our samples, the four genes were expressed in T-MSCs, and
more modestly in N-MSCs but not (GREM1 and LOXL2) or weakly so
(ITGA11 and ADAMTS12) in the tumor cells (data not shown). They
were also highly expressed in BM-MSCs, which promoted metastasis
to the spleen but less so to other organs. Assessment of the correlation
of the 4-gene expression in other data sets revealed signiﬁcant related-
ness between GREM1, ADAMTS12 and LOXL2 expression in NSCLC-
associated MSCs (Table S3). However, the same correlation was not
found in NSCLC-associated CAFs, the only signiﬁcant relatedness in the
latter being observed between ADAMTS12 and ITGA11 expression
(Table S3). Because of their strong co-expression and their reported
roles in ECM and tissue remodeling, we addressed the possibility that
GREM1, LOXL2, ADAMTS12 and ITGA11may constitute a candidate core
pro-metastatic MSC gene signature. As our primary tumor model, we
used sample 26 tumor cells, whichdisplayed amarked difference inme-
tastasis formation upon exposure to N- or T-MSCs (Fig. 5A).
We ﬁrst infected 26 N-MSCs with either Emerald control virus (N-
MSCEM) or with single-gene containing viruses at a low MOI to recapit-
ulate the increase in the corresponding gene expression observed in T-
MSCs (Figs. 3B and S7B). 26 T-MSCs infected with EM control virus (T-
MSCEM) were used as an additional control. As suggested by the dataset
analysis reported above, expression of the four genes appeared to be
linked as introduction of one gene increased the endogenous expression
levels of the others, with the exception of ADAMTS12. However, intro-
duction of ADAMTS12 augmented expression of the three other genes
(Fig. S7B). To overcome the difﬁculty of expressing multiple exogenous
genes in primary MSCs, we engineered MSCs that express each of the
four genes individually and equal numbers of the corresponding MSCs
were pooled to generate a bulk of MSCs expressing the four genes
(MSCGAIL). The MSC bulk was then co-injected with sample 26 tumor
cells (2000 cells per mouse) at a 1:1 MSCGAIL:tumor cell ratio and com-
pared with tumor cells injected with T-MSCEM or N-MSCEM. Similar to
our initial tumor cell/paired MSC co-injections (Fig. 2), we did not ob-
serve any difference in local tumor growth among the three conditions
(Fig. 7A). In contrast and similar to our observations using non-infected
MSCs, 26 tumor cells co-injected with T-MSCEM displayed higher meta-
static activity than those co-injected with N-MSCEM (Fig. 7A and B). In-
terestingly, following infection with the EM control virus, T-MSCs
displayed increased expression only of GREM1 and ITGA11 compared
to N-MSCEM, thereby displaying a slightly different proﬁle than non-infected T-MSCs (Fig. 3B and S7B) and possibly explaining the smaller
difference in metastasis promotion between T- and N-MSCEM than be-
tween the corresponding uninfected MSCs. Remarkably, N-MSCGAIL
clearly increased metastasis of tumor cells compared to N-MSCEM.
Both the number (Nb) and the area (A) of the metastases were en-
hanced by N-MSCGAIL (means: Nb = 95; A = 2.77%), to a degree that
was between that of N- (means: Nb = 47.1; A = 1.21%) and T-MSCEM
(means: Nb = 147; A = 6.7%) (Fig. 7A). Metastasis quantiﬁcation in
each organ showed that N-MSCGAILpromoted tumormetastases primar-
ily in liver, lung and spleen (Fig. 7B). Altogether our data suggest that
expression of GREM1, LOXL2, ITGA11 and ADAMTS12 by MSCs enhances
primary lung cancer metastasis. Consistent with these observations,
high expression of these four genes (especially LOXL2) in primary tu-
mors is associatedwith poor overall survival in patients with lung carci-
noma (Fig. S7C). Furthermore, patients with high expression of the four
genes have worse prognosis than patients with elevated levels of single
GREM1, ADAMTS12 or ITGA11 genes (Fig. S7D). Our data suggest that
these genes constitute a stromal pro-metastatic signature in MSCs
whose pharmacologic neutralization as a means to blunt lung carci-
noma metastasis will be worth exploring.
4. Discussion
Using primary lung carcinomas and corresponding tumor-
associated as well as non-tumoral adjacent tissue-derived MSCs, we
have demonstrated the ability of MSCs to selectively enhance tumor
metastasis without signiﬁcantly affecting local growth. As our experi-
ments were performed in NSGmice, the effects of MSCs were unrelated
to their immunosuppressive functions on T and NK cells (Aggarwal and
Pittenger, 2005; Galland et al., 2017; Uccelli et al., 2008). Instead, T-
MSCs most likely promoted metastasis by mechanisms related to func-
tions induced by tumor cells and the TME.
Most studies on the role of MSCs in cancer progression have been
done using BM-MSCs and established tumor cell lines, both of which
have limitations with respect to their representation of the physiologi-
cal setting. Despite sharing the same cell surface markers and similar
plasticity, BM- and T-MSCs display different features (McLean et al.,
2011). Although BM-MSCs are recruited to inﬂammatory sites and
may contribute to the TME, it seems likely that T-MSCs are primarily de-
rived from residentN-MSCs in tissueswithinwhich the tumor develops.
Consistent with this notion and unlike N-MSCs, BM-MSCs did not dis-
play the samemetastasis promoting ability toward SCCs as T-MSCs, sug-
gesting that tumor cells do not cause BM-MSCs to acquire all of the
features displayed by T-MSCs. However, recent observations from our
group indicate that T- and BM-MSCs display comparable immunosup-
pressive activity, albeit by distinct mechanisms (Galland et al., 2017),
which further underscores the difference in their effect on metastasis
by mechanisms unrelated to the immune response. Tumor cell lines,
on the other hand, may not recapitulate the heterogeneity of primary
tumor cultures in which cell subpopulations may display diverse re-
sponses to stromal cell-derived signals, only a few being endowed
with metastatic potential (Naxerova et al., 2017; Ramaswamy et al.,
2003). Accordingly, by secreting CXCL12 and IGF-1, mesenchymal stro-
mal cells from triple negative breast tumors have recently been shown
to positively select cancer clones with high Src activity and propensity
for bone metastasis (Zhang et al., 2013).
To explore stromal-tumor cell crosstalk that is biologically and clin-
ically relevant to human cancer progression we addressed the effects of
MSCs isolated from paired primary lung carcinoma samples (T-MSCs)
and normal adjacent tissues (N-MSCs) on the corresponding patient-
derived tumor cells and vice-versa. Tumor-associated MSCs displayed
a transcriptome distinct from that of N-MSCs, consistent with observa-
tions by others (Gottschling et al., 2013) and with the notion that
tumor cells and the TME condition the MSC phenotype and function
(Shi et al., 2017). Accordingly, co-culture with tumor cells resulted in
N-MSC up-regulation of several of the genes that characterized the T-
Fig. 5. In vivo effects of N- and T-MSCs on primary lung cancer cells andMSC:tumor cell interactions in three dimensional structures. (A) Results frommouse injectionswith 21, 26 and 32
primary cancer cells alone (CTRL; n=11, 3 and 13mice respectively) or in presence of pairedN- (n=15, 3, 14mice respectively) and T-MSCs (n=14, 3, 14mice respectively). For 21 and
32 tumors, 2 independent experiments were performed and data pooled together. Top panels: For each group of injection, total numbers of metastases per injected mouse are reported.
Means are depicted by horizontal lines. Groupswere compared using the nonparametric Kruskal-Wallis (K-W) testwith post-hoc Dunn'smultiple comparison test. Signiﬁcant differences
are reported and adjusted P-values indicated as * at P b 0.05. Lower panels: percentages of mice bearing metastases in 3–4 organs simultaneously in each group. See also Fig. S5.
(B) Spheroids of CFSE-labeled tumor cells alone or mixed with T-MSCs from patient 21 at a 1:1 tumor:MSC cell ratio included in a 3-D matrix. Cell dissemination and three
dimensional cell interactions were monitored by microscopy and the experiment performed in quadruplicate. One representative spheroid of tumor cells alone or mixed with T-MSCs
is shown at day 0 and day 2 and images taken at 4× magniﬁcation by light and ﬂuorescent microscopy. Scale bar = 200 μm. See also Fig. S6.
140 G. Fregni et al. / EBioMedicine 29 (2018) 128–145MSC transcriptome. Furthermore, exposure of N-MSCs to TGF-β, which
orchestrates repair- and cancer-associated tissue remodeling and plays
an important role in cancer progression (Ikushima and Miyazono,
2010), resulted in the induction of several genes expressed in T-MSCs
that were not induced by the tumor cells. These observations suggest
complementarity between the effects of tumor cells and those of the
TME in promoting N-MSC transition toward a T-MSC phenotype,consistent with the participation of both tumor cells and the TME
in shaping T-MSCs. It is noteworthy that several genes, which
were highly expressed in T-MSCs were induced neither by tumor
cells nor TGF-β in N-MSCs, suggesting the implication of other me-
diators from the TME. Normal tissue-associatedMSCs can therefore
transition toward a T-MSC phenotype in response to tumor cell and
TME queues.
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142 G. Fregni et al. / EBioMedicine 29 (2018) 128–145The most striking effect of T- and N-MSCs on primary lung carci-
noma cells was the selective promotion metastasis with little or no ef-
fect on tumor growth at the site of injection. This was also the case for
BM-MSCs, in albeit more limited manner and was in stark contrast to
the common observation that stromal cells, often termed CAFs, promote
local tumor growth ﬁrst and foremost. Human T-MSC implication in the
progression of other tumors, including ovarian carcinoma (McLean
et al., 2011), breast cancer (Yan et al., 2012) and hepatocellular carci-
noma (Yan et al., 2013) has been documented (Sun et al., 2014). How-
ever, to the best of our knowledge, the almost exclusive promotion of
primary lung carcinoma cell dissemination by MSCs has not been re-
ported before (Liu et al., 2014). Mesenchymal stem cells may acquire
different properties, probably with different kinetics, according to the
tumor cell type and the corresponding TMEwith which they are associ-
ated. Thus, N-MSCs from a patient with a composite tumor bearing pre-
dominant SCLC features were unable to promote metastasis of paired
primary tumor cells, raising the possibility that the TME rather than
the tumor cells played a dominant role in inducing the T-MSC pheno-
type in this case. However, the paucity of samples in our study precludes
any generalization on tumor-type-dependent effects.
Tumor-associatedMSCs modulated the primary lung carcinoma cell
transcriptome, causing upregulation of placenta genes, hypoxia-
induced transcripts and epithelial-mesenchymal-transition (EMT)-as-
sociated genes, all of which are reported to be related to tumor cell dis-
semination (Gilkes et al., 2014; Rousseaux et al., 2013; Tsai and Yang,
2013). Some of these genes, including GDF15, TGM2, VEGFA and
ZNF385A were also up-regulated in primary tumor cells from patient
32 after co-culture with N-MSCs. GDF15 expression is reported to be as-
sociatedwithmetastasis (AwYong et al., 2014; Li et al., 2016) and TGM2
(Agnihotri et al., 2013; H.-J. Kim et al., 2012) and VEGFA (Geng et al.,
2015; Mak et al., 2010) are implicated in EMT and the response to hyp-
oxia, respectively. High expression of VEGFA and ZNF385A correlate
with poor survival of patients with serous ovarian carcinoma (Elgaaen
et al., 2012). Thus, lung cancer MSCs appear to induce a gene signature
associated with aggressive tumor behavior, possibly explaining, at least
in part, the observed increase in metastasis.
Modulation of gene expression in both tumor cells and N-MSCs oc-
curred rapidly in vitro and was for themost part due to secreted factors,
as co-cultures were indirect. These observations support the largely
comparable effects of SCC-derived T- and N-MSCs on tumor spread ob-
served in our in vivo experiments. The difference in gene expression
changes between 21 and 32 primary tumor cells in response to MSCs,
which correlated with the degree of metastasis induction in vivo, may
reﬂect intrinsic tumor properties, as comparable gene modulation was
induced in each tumor by co-culture with either paired or allogeneic
MSCs (from patient 29). But how do the ratios of MSCs to tumor cells
used in our co-culture and co-injection experiments reﬂect the in vivo
situation in which the MSCs populations represents no more than 4%
of the tumor bulk and frequentlymuch less? And can the small numbers
of MSCs observed in the tumor bulk have a signiﬁcant functional impact
on tumor progression? One view is that the inﬂuence of MSCs may varyFig. 6. Effects of N- and T-MSCs on primary lung cancer cell transcriptome and invasiveness. (A–
N- or T-MSCs from the same patient or from patient 29. Two independent experiments were pe
data from 21 (circles) and 32 (triangles) tumor cells cultured alone (in green) or with N- (in b
(striped) after removal of sample and batch effects. Percentages of data variation explained by t
up-regulated by tumor cells afterMSC co-culture. For the analysis, results from co-cultureswith
as “+N-MSC” or “+T-MSC”. Genes up-regulated in 32 tumor cells culturedwith N-MSCs are rep
genes also overexpressed following T-MSC co-culture. Genes up-regulated in tumor 21 in the p
circles. The size of circles represents the numbers of up-regulated genes for each culture conditi
in the different conditions is listed (rectangles). (C) Gene ontology analysis of up-regulated ge
labeled tumor cells (upper chamber, medium without serum) from patients 21 and 32 throu
MSCs (lower chamber, medium with serum). Medium with serum in the absence of MSCs
condition were performed in duplicate. Following overnight incubation, images of CFSE-l
membrane after removal of non-invading cells from the upper chamber by washing the gel s
focus adjusted to the 8 μm insert pores by light microscopy) at 4× magniﬁcation. Scale ba
chamber at the end of the co-culture. Cells were counted on images taken by ﬂuorescent micr
light microscopy.over time and as a function of tumor heterogeneity. Early in tumor de-
velopment, when the tumor consists of a small cluster of cells, the
ratio of tumor cells to MSCs may be comparable, in which case MSCs
may have a signiﬁcant inﬂuence on tumor cell behavior and promote
earlymetastasis (Massagué andObenauf, 2016;Wan et al., 2013). How-
ever, even at later stages, the small numbers of MSCs may inﬂuence in-
dividual tumor cells or tumor cell subpopulations. Depending on the
properties and responsiveness of the latter, the effect of MSCs may
lead to detachment and dissemination of individual cells or cell cohorts.
Thus, even small numbers of MSCs may promote tumor progression.
An obvious question is by what mechanisms do MSCs promote
tumor dissemination? In response to tumor cells and the TME,
MSCs acquire the T-MSC phenotype, which may directly affect
tumor cells but may also create an environment that facilitates
tumor spread. By assessing the gene expression proﬁle of T-MSCs
and correlating individual gene expression with lung cancer evolu-
tion, we identiﬁed four genes that appear to be co-expressed in lung
cancer patients with poor prognosis. The four genes, GREM1, LOXL2,
ADAMTS12 and ITGA11, provide a candidate stromal signature that
may be functionally implicated in lung cancer dissemination.
These four genes were also highly expressed in BM-MSCs, which al-
though less potent in promoting multi-organ metastasis than T-
MSCs, induced metastasis to the spleen at a rate comparable to
that of T-MSCs. They may therefore constitute a core MSC pro-
metastatic gene signature, whose potency may be modulated by
the induction of other genes, possibly explaining the difference in
metastasis promotion observed between T- and BM-MSCs. Consis-
tent with this notion, expression of the four genes increased the
ability of N-MSCs to promote metastasis of tumor 26, without
quite reaching that of the corresponding T-MSCs. Each of the four
genes is suggested to participate in tumor progression. GREM1, pri-
marily expressed by stromal cells (Sneddon et al., 2006), is a bone
morphogenetic protein (BMP) antagonist implicated in tumor pro-
gression (Minsoo Kim et al., 2012b) and EMT (Karagiannis et al.,
2015). LOXL2, a member of the lysyl oxidase (LOX) family that en-
codes genes for copper-dependent amine oxidases, which partici-
pate in ECM stabilization by covalent cross-linking of collagen is
strongly associated with cancer progression (Wu and Zhu, 2015).
A pro-metastatic function of LOXL2 in murine lung cancer cells
that have undergone EMT has been attributed to its role in collagen
stabilization and activation of integrin signaling (Peng et al., 2017).
ITGA11, which together with integrin β1 forms a cell surface colla-
gen receptor, is involved in cell migration and collagen reorganiza-
tion (Tiger et al., 2001). High ITGA11 expression in the tumor stroma
is a marker of poor prognosis in NSCLC patients (Chong et al., 2006;
Zhu et al., 2007). ADAMTS12 is a member of the disintegrin and me-
talloproteinase with thrombospondin repeats gene family reported
to be endowed with a tumor protective role in several studies (El
Hour et al., 2010; Fontanil et al., 2014; Wang et al., 2011). However,
exogenous expression of ADAMTS12 confers an invasive phenotype
on trophoblastic cells through the induction of cell-matrixC) Analysis of RNA-Seq data from primary tumor cells cultured alone or in the presence of
rformedwith paired or 29MSCs. (A) Principal component analysis (PCA) plot of RNA-Seq
lue) or T-MSCs (in red) isolated from the same patient (ﬁlled symbols) or from patient 29
he two ﬁrst principal components (PC) are reported in brackets. (B) Venn diagram of genes
MSCs (N- or T-) from different patients (paired or 29) were pooled together and indicated
resented by a blue circle, containing a smaller darker one that represents the 2 overlapping
resence of N- or T-MSCs are respectively symbolized by a yellow and a green intersecting
on. The number of genes included in each region is indicated. Overlapping gene expression
nes in 21 tumor cells co-cultured with MSCs. See also Table S2. (D) Invasiveness of CFSE-
gh a matrigel membrane was assessed in transwell co-culture conditions with N- or T-
in the lower chamber was used as the control condition (CTRL). Experiments in each
abeled tumor cells invading the matrigel were captured at the level of the transwell
urface multiple times with PBS. Images were taken by ﬂuorescent microscopy (with the
r = 200 μm. The table indicates the numbers of CFSE-labeled tumor cells in the lower
oscopy at 4× magniﬁcation in the lower chamber, with the focus adjusted to the MSCs by
Fig. 7.N-MSCs overexpressingGREM1, LOXL2, ITGA11 andADAMTS12 increase themetastatic potential of paired tumor cells. Results from26 tumor cell co-injectionswith pairedN- (n=6)
or T-MSCs (n= 7) expressing the Emerald reporter gene (EM) or with a bulk of N-MSCs single expressing GREM1, LOXL2, ITGA11 and ADAMTS12 (GAIL; n= 7) in addition to the EM gene.
(A) Left: ultrasound (US) follow-up of tumor volume (mm3) from the day of cell injection to sacriﬁce is shown. Lines connect themean values for each group ofmice. Standard deviations
are indicated. Right: for each group, the tumor weight (g) quantiﬁcation of the total number of metastases and proportion of the total tissue area occupied mymetastases per mouse are
shown. Horizontal lines indicatemean values. (B) Number of metastases and the proportion of each affected organ occupied bymetastatic tumor growth permouse in the three groups of
mice are shown.Mean values are indicated by the horizontal lines. Groupswere compared using the nonparametric Kruskal–Wallis (K–W) testwith post-hoc Dunn'smultiple comparison
test. See also Fig. S6.
143G. Fregni et al. / EBioMedicine 29 (2018) 128–145interactions by a mechanism independent of its endogenous pro-
teolytic activity, which includes integrin up-regulation (Beristain
et al., 2011). Expression of ADAMTS12 in N-MSCs increased the ex-
pression of ITGA11 to a level comparable to that observed in T-
MSCs. Altogether, the known functions of the products of the four
genes provide a plausible mechanistic explanation for MSC promo-
tion of metastasis, which includes paracrine signaling that may
maintain cancer cell pluripotency and stimulate motility as well as
ECMmodiﬁcation that may facilitate migration. Their strong associ-
ation in lung carcinoma, suggesting shared regulatory mechanisms,
supports synergy among their effects, which in turnmay explain the
correlation of their expression with poor patient prognosis.
Most gene expression studies in cancer metastasis have focused
on tumor cells in the hope of identifying metastasis-speciﬁc gene
signatures or gene signatures that predict dissemination to a par-
ticular organ. However, stromal gene expression signatures that fa-
cilitate metastasis may be equally important particularly given that
they arise in genetically stable cells, which may be more readily
amenable to therapeutic targeting than genetically labile cancer
cells. The present study, based exclusively on primary stromal
and tumor cells, shows mutual transcriptome modulation between
tumor cells and MSCs and uncovers a tumor cell and TME-induced
stromal cell gene signature that promotes lung cancer metastasis.
These observations will help provide insight into how the TME con-
ditions cancer cell behavior and possibly open unsuspected thera-
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